PDCD1 and non-small cell lung carcinoma: Mass cytometry analysis of peripheral blood samples from 46 NSCLC patients, prior to PD-1 inhibitor administration, identified 7 phenotypically distinct populations of regulatory B cells (Bregs) [102].